International Journal of Collaborative Research on Internal Medicine & Public Health

ISSN - 1840-4529

David Anderson

Editorial Officel, International Journal of Collaborative Research on Internal Medicine and Public Health, Minnesota, USA


  • Editorial   
    A New Treatment Strategy for Multiple Myeloma with Monoclonal Antibodies
    Author(s): David Anderson*

    The approval of the first two monoclonal antibodies in the treatment of patients with relapsed and refractory multiple myeloma was a watershed moment for the multiple myeloma community in 2015. Despite early setbacks, monoclonal antibodies targeting CD38 (daratumumab) and signalling lymphocytic activation molecule F7 (SLAMF7) (elotuzumab) for patients with multiple myeloma became available in the same year for patients with multiple myeloma. Phase 3 clinical trials of combination treatments containing daratumumab or elotuzumab, in particular, have shown efficacy as well as a low safety profile. These monoclonal antibodies for multiple myeloma can kill target cells through antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent phagocytosis, and direct signalling cascade blocking. Furthermore, their immunomodulatory activities may inhibit th.. View More»
    DOI: 10.35248/1840-4529.22.14.341

    Abstract HTML PDF